This is a request for a Scientist Development Award (K21). The candidate proposes to obtain additional training in molecular neuroscience, and the correlation of genetic and molecular data with clinical presentation in Alzheimer's disease (AD). The career development plan involves increasing the candidate's conceptual knowledge of molecular neuroscience and clinical correlation. Further, the candidate will enhance or acquire technical skills in quantification of mRNA, cell surface protein detection, radioimmunoassay (RIA), metabolic labeling and immunoprecipitation of proteins, and molecular genetics. Skills in statistical analysis, particularly those relating to correlation of biological genetic, and clinical data, will also be enhanced. The research plan focuses on biological markers for clinical heterogeneity in AD. Apolipoprotein E (Apo E) and the beta-amyloid peptide (betaAP) are currently the best candidates for biological markers for Alzheimer's disease (AD). Most studies, however, have focused on the use of these markes in diagnosis. Few have addressed whether Apo E genotype and/or beta-amyloid expression represent dimensions of biological heterogeneity which correlate with clinical heterogeneity in AD. Patients with AD vary significantly along a number of clinical dimensions, yet there is no satisfactory biological explanation for this variation. Our central hypothesis is that Apo E genotype, cerebrospinal fluid (CSF) betaAP, and amyloid protein expression by leukocytes are correlated with clinical severity and rate of decline in AD. CSF betaAP will be determined with a RIA which discriminates among various betaAP species, some of which may be more pathogenic that others. Leukocyte amyloid expression will be measured with reverse transcription and polymerase chain reaction, and fluorescence activated cell sorting. A variety of neuropsychological, clinical, and brain imaging measures will be employed. It is hypothesized that subjects with the Apo epsilon4 allele will be predisposed to rapid clinical decline. Decreased total CSF betaAP and an increase in the expression of Kunitz protease inhibitor (KPI)- containing forms of beta-amyloid precursor protein (betaAPP) by leukocytes should also be associated with rapid decline. Rates of change will be determined from the amyloid measures, which should correlate with rates of clinical decline. Because there is good evidence that Apo E and betaAP interact in the pathophysiology of AD, subjects with the Apo epsilon4 allele should show larger decreases in CSF betaAP levels than do other SAD subjects. The combination of epsilon 4/epsilon4 genotype and markedly abnormal amyloid expression should characterize the most severely impaired subjects. Finally, quantification of CSF betaAP in AD subjects and controls will provide novel data on the contribution of the various betaAP species to the total CSF betaAP pool, which may give new insight into the basic biological processes by which betaAP is generated. Likewise, leukocyte data will be valuable in clarifying the processing of betaAPP by this important population of cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Scientist Development Award (K21)
Project #
5K21MH001239-05
Application #
2889829
Study Section
Mental Disorders of Aging Review Committee (MDA)
Program Officer
Goldschmidts, Walter L
Project Start
1995-07-01
Project End
2000-06-30
Budget Start
1999-09-15
Budget End
2000-06-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Stanford University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
O'Hara, Ruth; Brooks 3rd, John O; Friedman, Leah et al. (2007) Long-term effects of mnemonic training in community-dwelling older adults. J Psychiatr Res 41:585-90
de Medeiros, Kate; Kennedy, Quinn; Cole, Thomas et al. (2007) The impact of autobiographic writing on memory performance in older adults: a preliminary investigation. Am J Geriatr Psychiatry 15:257-61
O'Hara, Ruth; Schroder, Carmen M; Bloss, Cinnamon et al. (2005) Hormone replacement therapy and longitudinal cognitive performance in postmenopausal women. Am J Geriatr Psychiatry 13:1107-10
Murphy Jr, G M; Claassen, J D; DeVoss, J J et al. (2001) Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha -889 *1 allele. Neurology 56:1595-7
Murphy Jr, G M; Pollock, B G; Kirshner, M A et al. (2001) CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25:737-43
Gallagher-Thompson, D; O'Hara, R; Simmons, A et al. (2001) Apolipoprotein E epsilon4 allele affects the relationship between stress and depression in caregivers of patients with Alzheimer's disease. J Geriatr Psychiatry Neurol 14:115-9
Murphy Jr, G M; Zhao, F; Yang, L et al. (2000) Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease. Am J Pathol 157:895-904
Mauricio, M; O'Hara, R; Yesavage, J A et al. (2000) A longitudinal study of apolipoprotein-E genotype and depressive symptoms in community-dwelling older adults. Am J Geriatr Psychiatry 8:196-200
Dodel, R C; Du, Y; Bales, K R et al. (2000) Alpha2 macroglobulin and the risk of Alzheimer's disease. Neurology 54:438-42
Kahle, P J; Jakowec, M; Teipel, S J et al. (2000) Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 54:1498-504

Showing the most recent 10 out of 18 publications